412 related articles for article (PubMed ID: 32554615)
21. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629).
Grob JJ; Gonzalez R; Basset-Seguin N; Vornicova O; Schachter J; Joshi A; Meyer N; Grange F; Piulats JM; Bauman JR; Zhang P; Gumuscu B; Swaby RF; Hughes BGM
J Clin Oncol; 2020 Sep; 38(25):2916-2925. PubMed ID: 32673170
[TBL] [Abstract][Full Text] [Related]
22. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S; Demidov L; Moiseyenko V; Protsenko S; Semiglazova T; Odintsova S; Zukov R; Lazarev S; Makarova Y; Nechaeva M; Sakaeva D; Andreev A; Tarasova A; Fadeyeva N; Shustova M; Kuryshev I
Eur J Cancer; 2021 May; 149():222-232. PubMed ID: 33872982
[TBL] [Abstract][Full Text] [Related]
23. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.
Clingan P; Ladwa R; Brungs D; Harris DL; McGrath M; Arnold S; Coward J; Fourie S; Kurochkin A; Malan DR; Mant A; Sharma V; Shue H; Tazbirkova A; Berciano-Guerrero MA; Charoentum C; Dalle S; Dechaphunkul A; Dudnichenko O; Koralewski P; Lugowska I; Montaudié H; Muñoz-Couselo E; Sriuranpong V; Oliviero J; Desai J
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37848259
[TBL] [Abstract][Full Text] [Related]
25. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
Moreno V; Garrido P; Papadopoulos KP; De Miguel Luken MJ; Gil-Martin M; Aljumaily R; Rosen LS; Rietschel P; Mohan KK; Yoo SY; Stankevich E; Lowy I; Fury MG
Lung Cancer; 2021 May; 155():151-155. PubMed ID: 33831732
[TBL] [Abstract][Full Text] [Related]
26. Cemiplimab in advanced cutaneous squamous cell carcinoma.
Naik PP
Dermatol Ther; 2021 Nov; 34(6):e15184. PubMed ID: 34716727
[TBL] [Abstract][Full Text] [Related]
27. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
[TBL] [Abstract][Full Text] [Related]
28. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
[TBL] [Abstract][Full Text] [Related]
29. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel.
Lebas E; Marchal N; Rorive A; Nikkels AF
Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
[No Abstract] [Full Text] [Related]
31. Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies.
Kitano S; Shimizu T; Koyama T; Ebata T; Iwasa S; Kondo S; Shimomura A; Fujiwara Y; Yamamoto N; Paccaly A; Li S; Rietschel P; Sims T
Cancer Chemother Pharmacol; 2021 Jan; 87(1):53-64. PubMed ID: 33146741
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy.
Cowey CL; Robert NJ; Espirito JL; Davies K; Frytak J; Lowy I; Fury MG
Cancer Med; 2020 Oct; 9(20):7381-7387. PubMed ID: 32578965
[TBL] [Abstract][Full Text] [Related]
33. Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma.
Patel R; Chang ALS
Am J Clin Dermatol; 2019 Aug; 20(4):477-482. PubMed ID: 30737731
[TBL] [Abstract][Full Text] [Related]
34. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
[TBL] [Abstract][Full Text] [Related]
35. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
Hanna GJ; Dharanesswaran H; Giobbie-Hurder A; Harran JJ; Liao Z; Pai L; Tchekmedyian V; Ruiz ES; Waldman AH; Schmults CD; Riella LV; Lizotte P; Paweletz CP; Chandraker AK; Murakami N; Silk AW
J Clin Oncol; 2024 Mar; 42(9):1021-1030. PubMed ID: 38252908
[TBL] [Abstract][Full Text] [Related]
36. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.
Salzmann M; Leiter U; Loquai C; Zimmer L; Ugurel S; Gutzmer R; Thoms KM; Enk AH; Hassel JC
Eur J Cancer; 2020 Oct; 138():125-132. PubMed ID: 32882466
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.
Hughes BGM; Munoz-Couselo E; Mortier L; Bratland Å; Gutzmer R; Roshdy O; González Mendoza R; Schachter J; Arance A; Grange F; Meyer N; Joshi A; Billan S; Zhang P; Gumuscu B; Swaby RF; Grob JJ
Ann Oncol; 2021 Oct; 32(10):1276-1285. PubMed ID: 34293460
[TBL] [Abstract][Full Text] [Related]
39. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
40. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
